text Therapeutics (US:CNTX) Globenewswireยท2025-05-07 20:09Core Insights - Context Therapeutics Inc. is advancing its clinical pipeline with two product candidates, CTIM-76 and CT-95, currently in Phase 1 clinical trials, with initial clinical data expected in 2026 [2][3] - The company reported cash and cash equivalents of $89.4 million as of March 31, 2025, which is projected to fund operations into 2027 [2][10] - Research and development expenses increased to $3.5 million in Q1 2025 from $2.0 million in Q1 2024, primarily due to costs associated with CT-202 and CT-95 [5][9] Financial Performance - For the first quarter of 2025, Context reported a net loss of $4.6 million, compared to a loss of $3.7 million in the same period of 2024 [6][9] - General and administrative expenses rose to $2.1 million in Q1 2025 from $1.9 million in Q1 2024, driven by increased personnel costs [5][9] - Other income for Q1 2025 was approximately $1.0 million, up from $0.2 million in Q1 2024, mainly due to higher interest income [5][9] Upcoming Developments - The company plans to file an Investigational New Drug (IND) application for CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody, in mid-2026 [2][3] - Context will present at the Citizens Life Sciences Conference on May 8, 2025, and participate in one-on-one meetings at the D. Boral Capital Inaugural Global Conference on May 14, 2025 [5][4]